Zyclorin is a bit of a dark horse (at least to those of us who don't consult for pharmaceuticals) - one of those you hear no buzz about until they're almost done. It's 0.1% cyclosporine A and according to the NIH clinicals site, a Phase III study was completed almost two years ago. The Sirion site simply indicates it's in Phase III and Alcon is tight-lipped about the status.
Alcon to Purchase Ophthalmic Pharmaceutical Assets from Sirion
HUENENBERG, Switzerland, Jan 18, 2010 (BUSINESS WIRE) -- Alcon (NYSE: ACL), the world's leader in eye care, announced today that it will purchase the rights in the United States for two FDA-approved topical eye care products from Sirion Therapeutics, Inc. The two products purchased are Durezol(TM), a marketed ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, and Zirgan(TM), a recently approved antiviral for the treatment of acute herpetic keratitis (corneal ulcers). In addition to these marketed products, Alcon also acquired the global rights, excluding Latin America, for Zyclorin(TM). This product is currently in clinical development to treat dry eye and other ocular surface diseases.
No comments:
Post a Comment